Acumen is organized around development of effective therapeutics and diagnostics for treating Alzheimers disease and related neurodegenerative conditions. With the focus on disease-modifying drugs that block and reverse memory loss in Alzheimers, Acumen is focused on developing ADDL-Select antibodies that target soluble A? oligomers, which are now widely recognized as a key culprit in the disease process through their ability to inhibit nerve function, trigger early memory deficits and initiate nerve cell degeneration and downstream pathological events in Alzheimers. Acumens founders discovered synthetic soluble A? oligomers, called ADDLs for A?-Derived Diffusible Ligands to distinguish them from insoluble A? plaques. Acumens founders also pioneered the study of soluble A? oligomers and their pathological role in Alzheimers disease. Acumen owns or controls dominant intellectual property regarding ADDLs, soluble A? oligomers and related therapeutics and diagnostics.
